干扰素 β 治疗多发性硬化症。
Interferon β for Multiple Sclerosis.
机构信息
Buffalo Neuroimaging Analysis Center, Department of Neurology, University at Buffalo, State University of New York, Buffalo, New York 14203.
Jacobs MS Center, Department of Neurology, University at Buffalo, State University of New York, Buffalo, New York 14202.
出版信息
Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a032003. doi: 10.1101/cshperspect.a032003.
Abstract
Despite that the availability of new therapeutic options has expanded the multiple sclerosis (MS) disease-modifying therapy arsenal, interferon β (IFN-β) remains an important therapy option in the current decision-making process. This review will summarize the present knowledge of IFN-β mechanism of action, the overall safety, and the short- and long-term efficacy of its use in relapsing remitting MS and clinically isolated syndromes. Data on secondary progressive MS is also provided, although no clear benefit was identified.
摘要
尽管新的治疗选择的出现扩大了多发性硬化症 (MS) 的疾病修饰治疗武器库，但干扰素 β (IFN-β) 在当前的决策过程中仍然是一种重要的治疗选择。本综述将总结 IFN-β 的作用机制、总体安全性以及在复发缓解型 MS 和临床孤立综合征中的短期和长期疗效的现有知识。也提供了关于继发进展型 MS 的数据，尽管没有发现明确的益处。
相似文献
1
Interferon β for Multiple Sclerosis.干扰素 β 治疗多发性硬化症。
Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a032003. doi: 10.1101/cshperspect.a032003.
2
A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.多发性硬化症中干扰素-β的疗效和耐受性的荟萃分析，整体及按药物和疾病类型。
Clin Ther. 2010 Oct;32(11):1871-88. doi: 10.1016/j.clinthera.2010.10.006.
3
An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis.对干扰素β产品治疗多发性硬化症的EVIDENCE、INCOMIN和III期研究结果的审查。
Clin Ther. 2003 Jan;25(1):105-18. doi: 10.1016/s0149-2918(03)90013-0.
4
IFN-β and multiple sclerosis: from etiology to therapy and back.IFN-β 和多发性硬化症：从病因到治疗再到病因。
Cytokine Growth Factor Rev. 2015 Apr;26(2):221-8. doi: 10.1016/j.cytogfr.2014.10.010. Epub 2014 Oct 31.
5
Interferon-beta1b for the treatment of multiple sclerosis.β-干扰素1b用于治疗多发性硬化症。
Expert Opin Drug Metab Toxicol. 2008 Aug;4(8):1111-7. doi: 10.1517/17425255.4.8.1111.
6
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
7
PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.PRISMS：一个多发性硬化症关键临床试验系列的故事。
Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018.
8
Interferon-beta1a for the treatment of multiple sclerosis.β-干扰素1a用于治疗多发性硬化症。
Expert Opin Biol Ther. 2007 Apr;7(4):535-42. doi: 10.1517/14712598.7.4.535.
9
Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.干扰素β-1b：其在复发缓解型和继发进展型多发性硬化症中应用的综述
CNS Drugs. 2004;18(8):521-46. doi: 10.2165/00023210-200418080-00004.
10
Interferon-beta treatment for relapsing multiple sclerosis.干扰素-β治疗复发型多发性硬化症。
Expert Opin Biol Ther. 2008 Sep;8(9):1435-47. doi: 10.1517/14712598.8.9.1435.
引用本文的文献
1
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy.低强度I型干扰素信号传导促进CAR T细胞治疗疗效。
bioRxiv. 2025 May 20:2025.05.13.653878. doi: 10.1101/2025.05.13.653878.
2
The effect of interferon beta on quality of life in patients with multiple sclerosis: A systematic review and meta-analysis study.干扰素β对多发性硬化症患者生活质量的影响：一项系统评价和荟萃分析研究。
Curr J Neurol. 2024 Jul 5;23(3):176-188. doi: 10.18502/cjn.v23i3.17601.
3
Impact of interferon-β and dimethyl fumarate on nonlinear dynamical characteristics of electroencephalogram signatures in patients with multiple sclerosis.干扰素-β和富马酸二甲酯对多发性硬化症患者脑电图特征非线性动力学特性的影响。
Front Neuroinform. 2025 Feb 28;19:1519391. doi: 10.3389/fninf.2025.1519391. eCollection 2025.
4
Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review.不同治疗方法对多发性硬化症患者视网膜厚度变化的影响：一项综述
CNS Neurosci Ther. 2025 Jan;31(1):e70225. doi: 10.1111/cns.70225.
5
Machine learning for refining interpretation of magnetic resonance imaging scans in the management of multiple sclerosis: a narrative review.机器学习在多发性硬化症管理中优化磁共振成像扫描解读的应用：一项叙述性综述
R Soc Open Sci. 2025 Jan 22;12(1):241052. doi: 10.1098/rsos.241052. eCollection 2025 Jan.
6
A comprehensive overview of tolerogenic vaccine adjuvants and their modes of action.耐受性疫苗佐剂及其作用方式的全面概述。
Front Immunol. 2024 Dec 20;15:1494499. doi: 10.3389/fimmu.2024.1494499. eCollection 2024.
7
Understanding the role of potential biomarkers in attenuating multiple sclerosis progression via multiomics and network-based approach.通过多组学和基于网络的方法理解潜在生物标志物在减缓多发性硬化症进展中的作用。
PLoS One. 2024 Dec 19;19(12):e0314428. doi: 10.1371/journal.pone.0314428. eCollection 2024.
8
Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects.多发性硬化症：当前药物治疗及新兴治疗前景的叙述性综述。
Pharmacol Rep. 2024 Oct;76(5):926-943. doi: 10.1007/s43440-024-00642-0. Epub 2024 Aug 23.
9
CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients.克罗地亚和斯洛文尼亚多发性硬化症患者的 CCR5 Δ32 和 CTLA-4 +49 A/G 基因多态性与干扰素-β治疗反应。
Int J Mol Sci. 2024 Jul 5;25(13):7412. doi: 10.3390/ijms25137412.
10
The causal relationship between autoimmune diseases and age-related macular degeneration: A two-sample mendelian randomization study.自身免疫性疾病与年龄相关性黄斑变性的因果关系：两样本孟德尔随机化研究。
PLoS One. 2024 Jun 10;19(6):e0303170. doi: 10.1371/journal.pone.0303170. eCollection 2024.
本文引用的文献
1
Persistency of Neutralizing Anti-Interferon-β Antibodies in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon-β Depends on Antibody Titers, IgG Subclasses, and Affinity Maturation.皮下注射干扰素-β治疗的多发性硬化症患者中，中和性抗干扰素-β抗体的持续性取决于抗体滴度、IgG亚类和亲和力成熟度。
J Interferon Cytokine Res. 2017 Jul;37(7):317-324. doi: 10.1089/jir.2016.0080. Epub 2017 Apr 18.
2
Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.干扰素-β治疗多发性硬化症患者 6-12 年内的残疾进展标志物。
Mult Scler. 2018 Mar;24(3):322-330. doi: 10.1177/1352458517698052. Epub 2017 Mar 13.
3
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.多发性硬化症是一种长度依赖性中枢轴索性神经病吗？治疗延迟及异步进展型多发性硬化症假说的情况。
Mult Scler Relat Disord. 2017 Feb;12:70-78. doi: 10.1016/j.msard.2017.01.007. Epub 2017 Jan 17.
4
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.欧洲多发性硬化症患者中抗干扰素β和那他珠单抗药物抗体分析的临床实践：检测结果的描述性研究
PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.
5
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.根据对干扰素β（IFNβ）的治疗反应，多发性硬化症患者经IFNβ体外刺激后JAK-STAT信号通路的激活情况
PLoS One. 2017 Jan 19;12(1):e0170031. doi: 10.1371/journal.pone.0170031. eCollection 2017.
6
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.妊娠与多发性硬化症患者使用疾病修饰疗法：益处与风险
Mult Scler Int. 2016;2016:1034912. doi: 10.1155/2016/1034912. Epub 2016 Dec 18.
7
Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.皮下注射干扰素β-1a 治疗临床孤立综合征：III 期剂量频率盲法多中心 REFLEXION 研究的 3 年和 5 年结果。
J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):285-294. doi: 10.1136/jnnp-2016-314843. Epub 2016 Dec 30.
8
Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.干扰素在复发缓解型多发性硬化症中的比较疗效：一项真实世界研究的荟萃分析
Curr Med Res Opin. 2017 Mar;33(3):579-593. doi: 10.1080/03007995.2016.1276895. Epub 2017 Jan 11.
9
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.奥瑞珠单抗与干扰素β-1a 治疗复发型多发性硬化症的疗效比较。
N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.
10
Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.血清脂质谱变化可预测干扰素β-1a治疗的多发性硬化症患者的神经退行性变。
J Lipid Res. 2017 Feb;58(2):403-411. doi: 10.1194/jlr.M072751. Epub 2016 Dec 6.
Zotero 插件